

# Extended table of contents

Acknowledgements	5
Foreword by the Directors-General	6
An integrated health, trade and IP approach to respond to the COVID-19 pandemic	7
Executive Summary	16
<b>I. Medical technologies: the fundamentals</b>	<b>24</b>
<b>A. Public health and medical technologies: the imperative for international cooperation</b>	<b>26</b>
1. Policy coherence	26
2. Scope of the study	27
3. The need for this study	27
4. Who should read this study?	28
<b>B. The cooperating agencies: the WHO, WIPO and the WTO</b>	<b>29</b>
1. World Health Organization	29
2. World Intellectual Property Organization	30
3. World Trade Organization	31
4. Trilateral cooperation	31
5. Other international key stakeholders	32
<b>C. The global burden of disease and global health risks</b>	<b>33</b>
1. Current estimates of global and regional burden of disease	33
2. Trends: major cause groups contributing to the total disease burden	33
3. Trends in global health risks	35
<b>D. Factors shaping public health policy</b>	<b>36</b>
1. Seeking effective outcomes within a complex policy environment	36
2. Transforming policy intersections	36
3. Building stronger links between local, national and global levels	37
4. The empirical challenge: an accessible base for policy	39
<b>II. The policy context for action on innovation and access</b>	<b>42</b>
<b>A. Public health policy</b>	<b>44</b>
1. Health and human rights	44
2. Access to essential medicines: an indicator for the fulfilment of the right to health	46
3. Universal access and the UN Sustainable Development Goals	46
4. Public health, innovation and access in the WHO	48
(a) Resolutions dealing with public health, intellectual property and trade	48
(b) The Commission on Intellectual Property Rights, Innovation and Public Health	49
(c) The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property	49
(d) Other developments in the WHO	50

5. Cross-cutting efforts to tackle antimicrobial resistance	51
6. Regulation of health technologies	52
(a) Why regulate medical products?	53
(b) Clinical trials	54
(c) Research ethics	54
(i) Clinical trial ethics	54
(ii) Health databases and biobanks	55
(iii) Bioethics	55
(d) Biotherapeutic products	56
(i) Background	56
(ii) Pathways for the registration of biotherapeutic products	56
(iii) What will be the effect of SBPs on prices?	57
(e) Future of regulation	57
(f) Regulatory exclusivities	59
(g) Patent linkage	61
<b>B. Intellectual property, trade and other policy dimensions</b>	<b>63</b>
1. Intellectual property systems	63
(a) Introduction to IP systems	63
(b) Patent law and policy	66
(i) The rationale of the patent system	66
(ii) The international framework	66
(iii) Basic patent issues	68
(iv) Patent procedures	71
(v) Review procedures	72
(vi) Rights conferred by a patent	72
(vii) Exceptions and limitations to patent rights	73
(viii) Patent information	74
(ix) Patent status and legal status information	76
(x) Patent landscapes and medical technologies	78
(xi) Filing trends under the Patent Cooperation Treaty system	78
(c) Protection of test data	80
(i) How test data are protected	80
(ii) Innovation and access dimensions	82
(iii) Distinction between the protection of patents and of test data	82
(iv) Open access to test data	83
(d) Trademarks	83
(i) The trademark system	83
(ii) Trademarks and international non-proprietary names (INNs) for active pharmaceutical ingredients	85
(iii) Trademarks and unfair competition	86

(iv) Regulatory approval of proprietary names	86
(v) Trademark cluttering	86
(vi) Non-traditional marks	86
(vii) Standardized packaging	87
(e) Copyright	87
(i) Copyright and pharmaceutical package inserts	87
(ii) Exceptions and limitations – text and data mining	88
(iii) Licensing schemes	88
(iv) Orphan works access licensing schemes	88
(v) Software licensing and eHealth	88
(f) Enforcement	89
(i) The link between intellectual property right enforcement and public health	90
(ii) Enforcement provisions of the TRIPS Agreement	90
(iii) The WIPO Advisory Committee on Enforcement	90
(g) Flexibilities under the TRIPS Agreement and the Doha Declaration	90
(i) Flexibilities in the IP system	90
(ii) Background to the Doha Declaration	91
(iii) Content of the Doha Declaration	93
(iv) Implementation of the Doha Declaration	93
(v) Least-developed country transition periods	94
(h) Terms of accession to the WTO	94
2. Competition law and policy	95
(a) The dual function of competition law and policy	95
(b) The interface between competition law and policy, and IP protection	96
(i) Addressing competition policy concerns in the legal framework for IP protection	96
(ii) Enforcing competition law in the IP context	97
(c) Preserving innovation: merger control in the pharmaceutical sector	97
(d) Unfair competition	98
3. Trade policy settings	98
(a) Tariffs	98
(b) Non-tariff measures	99
(i) Sanitary and phytosanitary measures	99
(ii) Technical barriers to trade	99
(c) Trade in services	100
(i) The multilateral legal framework	101
(ii) The scope of GATS commitments in health-related sectors	101
(iii) The growing economic importance of trade in health services and the impact of GATS commitments	102
(iv) Challenges linked to the opening of trade in health services	102

4. Government procurement	103
(a) The importance of a transparent and competitive procurement process for the health sector	103
(b) Procurement of medical technologies and health services under the GPA	103
(i) GPA coverage	103
(ii) The magnitude of GPA parties' health-related procurement	105
5. Free trade agreements	105
(a) Trends in trade negotiations beyond the multilateral arena	105
(b) The non-discrimination principles and FTAs	106
(c) Intellectual property standards	106
(d) Investor–state dispute settlement	106
(e) Commitments in other areas	106
6. Resolving trade disputes at the WTO	107
<b>C. Economics of innovation and access to medical technologies</b>	<b>108</b>
<b>D. Genetic resources, traditional knowledge and traditional medicine</b>	<b>112</b>
1. Traditional medicine knowledge systems	112
2. Traditional medical knowledge in health and IP policy	113
3. Traditional medicines regulation	113
4. Concerns about misappropriation of traditional knowledge and genetic resources	114
5. New approaches to IP protection of traditional medical knowledge	115
(a) Why protect traditional knowledge?	116
(b) What is to be protected, and for whose benefit?	116
(c) What is it to be protected from?	116
(d) How can traditional knowledge be protected?	117
(e) Documentation	117
<b>III. Medical technologies: the innovation dimension</b>	<b>130</b>
<b>A. Historical pattern of medical R&amp;D</b>	<b>132</b>
1. Innovation for medical technologies in context	132
2. From early discoveries to “wonder drugs”	132
3. Growth and evolution of the pharmaceutical industry	133
4. From non-exclusive licensing to restricted production	133
5. Trends in R&D	134
<b>B. The current R&amp;D landscape</b>	<b>138</b>
1. A time of challenges and opportunities for pharmaceutical R&D	138
2. The key role of public-sector research in medical R&D	141
3. Medical R&D costs	142
4. Incentive models in the innovation cycle	143
(a) The innovation cycle	144
(b) Absence of self-sustaining innovation cycle in the case of small markets, low incomes or low sales volumes	144

(c) Building innovation networks	145
(d) Overview of innovation structures	145
(e) Vaccines: a distinct challenge for innovation	145
(i) New vaccine innovation in the 21st century	146
(ii) The role of developing-country manufacturers	146
5. Challenges in cancer medicines R&D	147
6. Orphan drugs and orphan indications	148
7. Registration of clinical trials in pharmaceutical product development	148
<b>C. Overcoming market failures in medical product R&amp;D</b>	<b>151</b>
1. Diseases disproportionately affecting people in developing countries	151
2. Antimicrobials and antimicrobial resistance	152
3. The WHO R&D Blueprint for Action to Prevent Epidemics	154
4. WHO Expert Working Groups on R&D financing	155
5. Novel approaches to biomedical R&D	155
(a) Monitoring health R&D	156
(b) Grants	156
(c) Prizes	156
(d) Advance market commitments and advance purchase commitments	158
(e) Priority review vouchers	158
(f) Tax breaks for companies	158
(g) Patent pools	160
(h) Open source drug discovery and development	161
(i) A global binding framework for R&D and a pooled fund for R&D	161
6. Product development partnerships	161
7. Research for neglected diseases: the role of pharmaceutical companies	163
8. WIPO Re:Search – Mobilizing intellectual property for global health	163
<b>D. Intellectual property rights in the innovation cycle</b>	<b>166</b>
1. IP management within the broader legal and policy framework at national and international levels	166
2. Intellectual property and the product development process	168
3. Patent filing strategies in the public and private sectors and the exercise of patent rights	168
4. Pre-grant issues: questions of patentability	169
(a) Patenting material that exists in nature	169
(b) Incremental innovation and evergreening	171
(i) Examples of incremental innovation	171
(ii) Evergreening	172
(c) Medical indication claims	174
5. Post-grant issues: questions related to the use of patents	176
(a) Research exception	176
(b) Research tools	176
(c) Licensing and assignment with respect to innovation	177
(d) Patents in R&D agreements and other forms of collaboration	177

(e) Patent clusters and patent thickets	178
(f) Freedom-to-operate issues	178
(i) Defining freedom to operate	179
(ii) Freedom-to-operate strategies	179
<b>E. Sharing of influenza viruses and access to vaccines and other benefits</b>	<b>180</b>
1. WHO Global Influenza Surveillance and Response System	180
2. Intellectual property rights in the context of PIP negotiations	180
3. The PIP Framework	181
4. The PIP Framework and genetic sequence data	182

## **IV. Medical technologies: the access dimension** **190**

<b>A. The context: health-systems-related determinants of access</b>	<b>192</b>
1. Universal health coverage	193
2. International access frameworks: the value chain of medicines and health products	194
3. The meaning and measurement of “access”	195
Affordability	196
Availability	196
4. Generic medicines policies, price controls and reference pricing	196
(a) Generic medicines policies	196
(i) Supply-side measures	196
(ii) Demand-side measures	197
(iii) A comparison of selected generic medicines policies	198
(b) Price control	198
(c) Reference pricing	198
(i) External reference pricing	198
(ii) Internal reference pricing	198
(d) Health technology assessments	199
(e) Market entry agreements (MEAs)	200
(i) Volume limitations	200
(ii) Health-outcome-based agreements	201
(f) Transparency across the value chain of medicines and health products	201
(g) Differential pricing strategies	201
5. Taxes	203
6. Mark-ups	204
7. Rational selection and use of medicines	204
8. Effective and efficient procurement mechanisms	206
(a) Principles for effective procurement	206
(b) Tendering	206
(c) Procurement and patent information	207

(d) Collective negotiation and pooled procurement	207
(e) Reliable health and supply systems	208
9. Sustainable financing	209
10. Manufacturing and technology transfer	209
11. Regulatory mechanisms and access to medical technologies	210
(a) WHO prequalification	212
(b) Regulation of medical devices	212
(c) Quality assurance by national medicines regulatory authorities	213
(d) Regulatory cooperation and convergence: reducing barriers from technical regulations and assessment procedures	213
(e) Collaborative procedures for accelerated registration	213
12. Substandard and falsified (SF) medical products	214
(a) Types of SF medical products	214
(b) Counterfeit medical products and the TRIPS Agreement	215
(c) The impact of SF medicines	215
(d) How can SF medical products be combated?	215
<b>B. Access to health products in specific areas</b>	<b>217</b>
1. HIV/AIDS	217
2. Antimicrobial resistance	219
3. Tuberculosis	220
4. Non-communicable diseases	221
5. Hepatitis C virus	224
6. Paediatric medicines	225
7. Vaccines	226
8. Medical devices	227
<b>C. Intellectual-property-related determinants of access</b>	<b>229</b>
1. Determinants of access prior to patent grant	230
(a) Diagnostic, surgical or therapeutic methods for the treatment of humans or animals	230
(b) Patent examination and patent registration	231
(c) Patent quality	232
2. Pre-grant and post-grant review procedures	232
3. Post-grant determinants of access	233
(a) Exceptions and limitations to patent rights	234
(i) Regulatory review (or “Bolar”) exception	234
(ii) Compulsory licensing and government use	235
(iii) The Special Compulsory Licensing System: an additional flexibility aimed at enhancing access to medicines	241
(b) Voluntary licensing agreements	244
(c) Socially responsible licensing policies and management of IP developed at public institutions	245

(d) March-in rights	246
(e) Open source licensing	246
(f) Exhaustion of rights and parallel imports	246
(i) International exhaustion	247
(ii) National exhaustion	247
(iii) Regional exhaustion	247
(iv) Policy options for exhaustion regimes	247
(g) Patent term extension and supplementary protection certificates	248
(i) Statutory mechanisms to extend the term of a patent	248
(ii) Supplementary protection certificates	249
(h) Enforcement of IP	250
4. Patent information and its relationship with public health policy	252
5. Review of relevant provisions in free trade agreements	252
(a) Review of selected IP provisions	252
(i) Patent law	258
(ii) Patent term extension	258
(iii) Grounds for granting compulsory licences	258
(iv) Exhaustion regime	258
(v) Regulatory exclusivities	258
(vi) Patent linkage	259
(vii) Enforcement	259
(viii) Reaffirmation of TRIPS flexibilities and Doha Declaration principles	259
(b) Investor–state dispute settlement	259
(c) Major actors in FTAs	260
(d) Economic impact analysis	260
(e) The role of international organizations	261
<b>D. Other trade-related determinants of access</b>	<b>262</b>
1. International trade and tariff data of health products	262
(a) International trade in health-related products	262
(b) Tariff policy for health-related products	267
2. Competition law and policy	270
(a) Application of competition law and policy to manufacturers of originator products	270
(i) Strategic patenting	271
(ii) Patent litigation	271
(iii) Refusal to deal and restrictive licensing practices as abuse of dominance	272
(iv) Interface of regulatory systems and competition law	274
(b) Competition law and policy in relation to the generics sector	274
(c) Application of competition policy to other actors in the health sector	276
(d) The role of competition policy with regard to public procurement markets	277



<b>Annex I. Resolutions of the UN General Assembly and UN Human Rights Council Key Reports of the UN Special Rapporteur on the Right to Health</b>	<b>292</b>
Selected Resolutions of the United Nations General Assembly	294
Selected Resolutions of the United Nations Human Rights Council	295
Key Reports of the United Nations Special Rapporteur on the Right to Health	296
<b>Annex II. Selected Resolutions and Decisions of the World Health Assembly</b>	<b>298</b>
<b>Annex III. Special Compulsory Licences for Export of Medicines</b>	<b>302</b>
<b>A. Operation of the System: context and scope</b>	<b>304</b>
1. What Is the System?	304
2. What products are covered by the System?	304
<b>B. Legal basis</b>	<b>304</b>
<b>C. Use of the System</b>	<b>304</b>
1. Who can use the System as importers and exporters?	304
2. How can the System be used by WTO members?	304
(a) How does an importing member use the System?	305
(i) Notifying general intention to use the System	305
(ii) Notifying the need to import specific pharmaceutical products	305
(b) How does an exporting member use the System?	306
3. Do regulatory authorities have to approve products manufactured under a special compulsory licence?	306
4. Which safeguards against diversion need to be put in place?	306
5. How can the System be used at the regional level?	306
6. What does the WTO General Council Chairman's statement add?	307
<b>D. Domestic implementation</b>	<b>307</b>
1. Importing members	307
2. Exporting members	308
3. Regional mechanism	308
<b>Bibliography</b>	<b>310</b>
<b>Abbreviations</b>	<b>329</b>
<b>List of figures, tables and boxes</b>	<b>334</b>
<b>Extended table of contents</b>	<b>339</b>